GROWTHFORGE · BEACON · SOURCE-BACKED SIGNAL
A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma
NCT01987492 is on the Cheap-to-Truth Radar because its public ClinicalTrials.gov record contains a recent development signal worth inspecting. This page is not a recommendation or diligence conclusion.
Priority to inspect82/100
StatusTERMINATED
PhasePHASE2
Lead sponsorHoffmann-La Roche
Last update2026-11-10
Public-record facts
| Intervention | Lebrikizumab (DRUG), Placebo (DRUG) |
|---|---|
| Condition | Asthma |
| Enrollment | 230 |
| Why stopped | Sponsor decision to discontinue lebrikizumab development for the treatment of asthma. |
| Results posted | Yes |
Why Beacon surfaced it
- The record is terminated and was updated 2026-11-10.
- It is an interventional PHASE2 study with a named drug/drug intervention.
- The lead sponsor is classified as industry.
- The record states a reason for stopping, creating a concrete diligence question.
- ClinicalTrials.gov indicates posted results are available.
What Cheap-to-Truth would verify next
- Was the stopping reason scientific, operational, financial, strategic, or mixed?
- What human safety and efficacy evidence actually exists beyond the registry summary?
- Who controls the relevant rights, and are they practically obtainable?
- Is there an indication and endpoint where a smaller experiment could answer the key decision?
- Would the resulting data be usable by the regulator that matters?
Source: ClinicalTrials.gov NCT01987492. Registry information is sponsor/investigator submitted; verify primary evidence before making development decisions.